NCT07476326 2026-03-17
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
Biocon Limited
Duke University
M.D. Anderson Cancer Center
McMaster University
AccSalus Biosciences, Inc.
Petrov, Andrey
Hangzhou DAC Biotechnology Co., Ltd.
Vastra Gotaland Region
Peking University Cancer Hospital & Institute
Vastra Gotaland Region